Raise closed, search for fresh raises on Seedstage

Houston, TX

Advancing AI-driven precision medicine by integrating genomics for predictive healthcare solutions.

• Breakthrough AI technology: Developing AI models that predict disease risks and optimize treatments.
• Cost reduction in RNA sequencing: BIRT technology lowers RNAseq costs fivefold, increasing accessibility.
• Clinical validation: Collaborating with leading institutions like Harvard Medical School and MD Anderson.
• Experienced leadership: Founded by former MIT and Rice University professors with successful biotech ventures.
• Global expansion: Facilities in the U.S., China, and India to scale genomic data collection.

Biostate AI is raising funds to advance its AI-driven precision medicine platform, leveraging genomics to predict individual health changes and optimize treatment strategies. By addressing critical barriers in RNA sequencing costs and AI-driven biological analysis, Biostate AI is pioneering a new era where medicine is tailored to each individual. Its proprietary BIRT technology significantly reduces the cost of RNA sequencing, making genomic data more accessible for both research and clinical applications. With clinical collaborations at leading institutions like Harvard Medical School and MD Anderson Cancer Center, the company is focused on developing AI models that help predict disease risk, personalize treatments, and improve drug safety.

The company is positioned at the intersection of AI and biotech, with a global presence in the U.S., China, and India to scale data collection efforts. Backed by top venture capital firms and industry experts, Biostate AI has analyzed thousands of biological samples, demonstrating promising results in leukemia risk assessment and drug safety predictions. The funds raised will support AI training through expanded RNA dataset collection, new clinical partnerships, and FDA approval processes for its AI-driven tests. This investment provides an opportunity to be part of the future of precision medicine, helping to bridge the gap between cutting-edge genomics and practical healthcare solutions.

Company Info

Biostate AI is transforming healthcare through AI-powered genomics, enabling predictive diagnostics and personalized treatments at scale.

Biostate AI is pioneering the integration of artificial intelligence and genomics to revolutionize personalized medicine. The company’s proprietary BIRT technology significantly reduces RNA sequencing costs, making high-quality genomic data more accessible for predictive healthcare applications. By leveraging AI, Biostate AI aims to predict diseases before they manifest, tailor treatments to individual genetic profiles, and enhance drug safety with high accuracy. With clinical collaborations spanning top hospitals like Harvard Medical School, MD Anderson, and Cornell, the company is driving real-world applications of AI-powered precision medicine.

Founded by former MIT and Rice University professors, Biostate AI has secured backing from top venture capital firms and industry experts. The company operates globally, with subsidiaries in India and China, and expects to scale to over 5 million human RNAseq datasets by 2028. Its partnerships with leading hospitals and research institutions position it at the forefront of AI-driven healthcare advancements, with the goal of FDA approval and widespread clinical adoption.